\-\ Texto\\:\\ \ \(0\)\
\-\ radiation\\ therapy\\ is\\ the\\ usual\\ treatment\\ for\\ symptomatic\\ metastatic\\ prostate\\ disease\\,\\ but\\ current\\ research\\ is\\ directed\\ at\\ the\\ utilization\\ of\\ bisphosphonates\\.\\ these\\ drugs\\ inhibit\\ bone\\ resorption\\ as\\ well\\ as\\ modify\\ the\\ microenvironment\\,\\ thus\\ making\\ tumor\\ growth\\ less\\ favorable\\ \\(eaton\\ and\\ coleman\\)\\.\ \(0\)\
\-\ tc99m\\ mcp\\ bone\\ scan\\ \\(posterior\\ view\\)\\ show\\ multiple\\ areas\\ of\\ increased\\ radiopharmaceutical\\ uptake\\ in\\ the\\ spine\\ and\\ in\\ the\\ left\\ posterior\\ sixth\\ rib\\ consistent\\ with\\ metastases\\ from\\ the\\ patient\\‚\\Ä\\ôs\\ prostate\\ cancer\\.\ \(0\)\
\-\ axial\\ ct\\ images\\ \\(bone\\ windows\\)\\ of\\ the\\ chest\\ at\\ the\\ level\\ of\\ the\\ sixth\\ rib\\ shows\\ pathologic\\ fracture\\ through\\ osteolytic\\ mass\\ of\\ the\\ left\\ posterior\\ rib\\ with\\ associated\\ pleural\\ reaction\\.\\ \ \(0\)\
\-\ axial\\ ct\\ images\\ of\\ the\\ chest\\ \\(bone\\ windows\\)\\ also\\ show\\ osteosclerotic\\ and\\ osteolytic\\ metastases\\ of\\ the\\ thoracic\\ spine\\.\\ \\ \ \(0\)\
\-\ p\\-a\\ radiograph\\ shows\\ pathological\\ fracture\\ through\\ osteolytic\\ lesion\\ of\\ the\\ left\\ posterior\\ sixth\\ rib\\ consistent\\ with\\ osteolytic\\ metastasis\\ from\\ patient\\‚\\Ä\\ôs\\ prostate\\ cancer\\.\ \(0\)\
\-\ metastatic\\ prostate\\ cancer\ \(4\)\
\-\ metastases\\ from\\ prostate\\ cancer\ \(2\)\
\-\ or\\ rarely\\ metastases\\ from\\ other\\ cancers\\ \\(lung\\,urinary\\ bladder\\)\ \(1\)\
\-\ paget\\‚\\Ä\\ôs\\ disease\\ \ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ 73\\-year\\-old\\ man\\ with\\ recently\\ diagnosed\\ prostate\\ cancer\\ presents\\ with\\ back\\ pain\\ and\\ acute\\ onset\\ of\\ left\\-sided\\ pleuritic\\ chest\\ pain\\.\ \(1\)\
\-\ prostate\\ cancer\\ typically\\ presents\\ after\\ the\\ age\\ of\\ 50\\ years\\ and\\ once\\ a\\ patient\\ in\\ the\\ united\\ states\\ reaches\\ this\\ age\\,\\ his\\ chance\\ for\\ developing\\ prostate\\ cancer\\ increases\\ with\\ each\\ decade\\ until\\ age\\ 90\\.\\ ethnicity\\ also\\ plays\\ a\\ factor\\ with\\ the\\ incidence\\ of\\ black\\ men\\ at\\ 137\\/100\\,000\\ and\\ white\\ men\\ at\\ 101\\/100\\,000\\ \\(boyle\\ et\\ al\\)\\.\\ \\ the\\ usual\\ site\\ for\\ metastases\\ is\\ the\\ spine\\ due\\ to\\ metastatic\\ cells\\ traveling\\ via\\ batson\\‚\\Ä\\ôs\\ plexus\\ of\\ veins\\.\\ however\\,\\ its\\ location\\ in\\ comparison\\ to\\ the\\ prostate\\ is\\ not\\ the\\ only\\ reason\\ for\\ metastatic\\ disease\\ developing\\ in\\ the\\ spine\\.\\ according\\ to\\ eaton\\ and\\ coleman\\ prostate\\ cancer\\ has\\ a\\ predilection\\ for\\ bone\\ over\\ other\\ tissues\\ due\\ to\\ \\‚\\Ä\\úselective\\ adherence\\,\\‚\\Ä\\ù\\ in\\ which\\ prostatic\\ cancer\\ cell\\‚\\Ä\\ôs\\ surface\\ molecules\\ bind\\ to\\ collagen\\ derived\\ from\\ bone\\ matrix\\.\\ this\\ is\\ also\\ why\\ prostate\\ metastases\\ can\\ be\\ found\\ in\\ other\\ bones\\ throughout\\ the\\ skeleton\\.\\ once\\ located\\ there\\,\\ the\\ tumor\\ will\\ find\\ an\\ environment\\ well\\ suited\\ for\\ growth\\ due\\ to\\ the\\ abundance\\ of\\ growth\\ factors\\ \\(berruti\\ et\\ al\\)\\.\\ \ \(0\)\
\-\ while\\ it\\ is\\ well\\ known\\ that\\ prostate\\ metastases\\ are\\ osteosclerotic\\,\\ it\\ is\\ unusual\\ for\\ osteolytic\\ lesions\\ to\\ be\\ present\\.\\ while\\ the\\ pathogenesis\\ is\\ still\\ largely\\ unknown\\,\\ osteosclerotic\\ and\\ osteolytic\\ lesions\\ seem\\ to\\ develop\\ due\\ the\\ interplay\\ between\\ different\\ growth\\ factors\\ located\\ in\\ bone\\ and\\ the\\ tumor\\ cells\\ themselves\\.\\ interleukin\\ 6\\,\\ tumor\\ necrosis\\ factor\\,\\ and\\ parathyroid\\ hormone\\ related\\ peptide\\ for\\ osteolytic\\ lesions\\ and\\ transforming\\ growth\\ factor\\ and\\ fibroblastic\\ growth\\ factor\\ for\\ osteosclerotic\\ \\(berruti\\ et\\ al\\)\\.\\ \ \(0\)\
\-\ the\\ imaging\\ workup\\ for\\ metastatic\\ prostate\\ cancer\\ begins\\ with\\ a\\ bone\\ scan\\,\\ which\\ has\\ largely\\ replaced\\ the\\ skeletal\\ survey\\.\\ according\\ to\\ manyak\\ et\\ al\\ a\\ bone\\ scan\\ detects\\ bone\\ metastases\\ in\\ 25\\%\\ of\\ patients\\ with\\ a\\ normal\\ skeletal\\ survey\\.\\ in\\ a\\ positive\\ skeletal\\ survey\\,\\ 50\\%\\ of\\ bone\\ marrow\\ must\\ be\\ replaced\\ by\\ metastases\\,\\ where\\ only\\ 10\\%\\ of\\ marrow\\ needs\\ replacement\\ for\\ a\\ bone\\ scan\\ to\\ be\\ positive\\ \\(wilkinson\\ and\\ hamdy\\)\\.\\ however\\,\\ radiographs\\ are\\ still\\ helpful\\ when\\ evaluating\\ osteosclerotic\\ metastases\\ in\\ order\\ to\\ differentiate\\ these\\ lesions\\ from\\ osteoarthritis\\,\\ which\\ is\\ also\\ common\\ in\\ the\\ elderly\\ male\\ patient\\ and\\ can\\ produce\\ a\\ positive\\ bone\\ scan\\ but\\ usually\\ in\\ the\\ periarticular\\ areas\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ berruti\\ a\\,\\ dogliotti\\ l\\,\\ tucci\\ m\\,\\ tarabuzzi\\ r\\,\\ fontana\\ d\\,\\ angeli\\ a\\.\\ metabolic\\ bone\\ disease\\ induced\\ by\\ prostate\\ cancer\\:\\ rationale\\ for\\ the\\ use\\ of\\ bisphosphonates\\.\\ j\\ urol\\.\\ 2001\\ dec\\;166\\(6\\)\\:2023\\-31\\.\ \(0\)\
\-\ boyle\\ p\\,\\ severi\\ g\\,\\ giles\\ gg\\.\\ the\\ epidemiology\\ of\\ prostate\\ cancer\\.\\ urol\\ clin\\ north\\ am\\.\\ 2003\\ may\\;30\\(2\\)\\:209\\-17\\.\ \(0\)\
\-\ eaton\\ cl\\ and\\ coleman\\ re\\.\\ pathophysiology\\ of\\ bone\\ metastases\\ from\\ prostate\\ cancer\\ and\\ the\\ role\\ of\\ bisphosphonates\\ in\\ treatment\\.\\ \\ cancer\\ treat\\ rev\\.\\ 2003\\ jun\\;29\\(3\\)\\:189\\-98\\.\ \(0\)\
\-\ manyak\\ mj\\,\\ javitt\\ m\\,\\ kang\\ ps\\,\\ kreuger\\ wr\\,\\ storm\\ es\\.\\ the\\ evolution\\ of\\ imaging\\ in\\ advanced\\ prostate\\ cancer\\.\\ urol\\ clin\\ north\\ am\\.\\ 2006\\ may\\;33\\(2\\)\\:133\\-46\\,\\ v\\.\ \(0\)\
\-\ wilkinson\\,\\ ba\\,\\ hamdy\\,\\ fc\\.\\ state\\-of\\-the\\-art\\ staging\\ in\\ prostate\\ cancer\\.\\ bju\\ int\\.\\ 2001\\ mar\\;87\\(5\\)\\:423\\-30\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ prostate\\:\\ 0\\.45388760033630204\ \(0\)\
\-\ cancer\\:\\ 0\\.2774436351830828\ \(0\)\
\-\ metastases\\:\\ 0\\.2315139735398488\ \(0\)\
\-\ osteolytic\\:\\ 0\\.21340910981119213\ \(0\)\
\-\ bone\\:\\ 0\\.21307126222031494\ \(0\)\
\-\ osteosclerotic\\:\\ 0\\.18725820740899402\ \(0\)\
\-\ the\\:\\ 0\\.1870073699905219\ \(0\)\
\-\ growth\\:\\ 0\\.12880008793458025\ \(0\)\
\-\ eaton\\:\\ 0\\.12490024545061099\ \(0\)\
\-\ coleman\\:\\ 0\\.12490024545061099\ \(0\)\
\-\ berruti\\:\\ 0\\.12490024545061099\ \(0\)\
\-\ urol\\:\\ 0\\.11235492444539641\ \(0\)\
\-\ of\\:\\ 0\\.11208258349991834\ \(0\)\
\-\ in\\:\\ 0\\.10362108933275956\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.10036851450139292\ \(0\)\
\-\ factor\\:\\ 0\\.09766105587265761\ \(0\)\
\-\ rib\\:\\ 0\\.09511879531746574\ \(0\)\
\-\ for\\:\\ 0\\.0946870605838713\ \(0\)\
\-\ sixth\\:\\ 0\\.0903194344561543\ \(0\)\
\-\ and\\:\\ 0\\.08607243925673724\ \(0\)\
\-\ survey\\:\\ 0\\.08532695253620236\ \(0\)\
\-\ boyle\\:\\ 0\\.08326683030040734\ \(0\)\
\-\ manyak\\:\\ 0\\.08326683030040734\ \(0\)\
\-\ hamdy\\:\\ 0\\.08326683030040734\ \(0\)\
\-\ al\\:\\ 0\\.08274113955064434\ \(0\)\
\-\ et\\:\\ 0\\.08157456118361377\ \(0\)\
\-\ wilkinson\\:\\ 0\\.07956590164629862\ \(0\)\
\-\ scan\\:\\ 0\\.07722726861061292\ \(0\)\
\-\ from\\:\\ 0\\.07237613235740742\ \(0\)\
\-\ to\\:\\ 0\\.071591873971689\ \(0\)\
\-\ metastatic\\:\\ 0\\.0713906728353355\ \(0\)\
\-\ skeletal\\:\\ 0\\.07080210924218996\ \(0\)\
\-\ spine\\:\\ 0\\.06879107155338843\ \(0\)\
\-\ is\\:\\ 0\\.06416533679481459\ \(0\)\
\-\ north\\:\\ 0\\.060212956304102866\ \(0\)\
\-\ due\\:\\ 0\\.05985843483130574\ \(0\)\
\-\ lesions\\:\\ 0\\.05980559767052018\ \(0\)\
\-\ largely\\:\\ 0\\.05951048569271119\ \(0\)\
\-\ replaced\\:\\ 0\\.05885823591312252\ \(0\)\
\-\ windows\\:\\ 0\\.056391130344087756\ \(0\)\
\-\ clin\\:\\ 0\\.05464725205194133\ \(0\)\
\-\ tumor\\:\\ 0\\.054468360785999544\ \(0\)\
\-\ usual\\:\\ 0\\.05407057947846833\ \(0\)\
\-\ posterior\\:\\ 0\\.05384882387310188\ \(0\)\
\-\ men\\:\\ 0\\.05301622253056045\ \(0\)\
\-\ according\\:\\ 0\\.052375425215653214\ \(0\)\
\-\ positive\\:\\ 0\\.051464442292817374\ \(0\)\
\-\ developing\\:\\ 0\\.049827256830036255\ \(0\)\
\-\ 2001\\:\\ 0\\.049150827928616615\ \(0\)\
\-\ am\\:\\ 0\\.049150827928616615\ \(0\)\
\-\ age\\:\\ 0\\.04903248041677944\ \(0\)\
\-\ also\\:\\ 0\\.04898186230456023\ \(0\)\
\-\ once\\:\\ 0\\.04893605065094372\ \(0\)\
\-\ 2003\\:\\ 0\\.046856927047341186\ \(0\)\
\-\ still\\:\\ 0\\.04612632817592754\ \(0\)\
\-\ with\\:\\ 0\\.0458793625159848\ \(0\)\
\-\ factors\\:\\ 0\\.04404287150167461\ \(0\)\
\-\ disease\\:\\ 0\\.04371194399522708\ \(0\)\
\-\ marrow\\:\\ 0\\.043269386350172606\ \(0\)\
\-\ be\\:\\ 0\\.04224318454308602\ \(0\)\
\-\ modify\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ microenvironment\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ interleukin\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ transforming\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ dogliotti\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ tucci\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ tarabuzzi\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ fontana\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ angeli\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ severi\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ giles\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ javitt\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ kreuger\\:\\ 0\\.04163341515020367\ \(0\)\
\-\ chest\\:\\ 0\\.0412255809365144\ \(0\)\
\-\ located\\:\\ 0\\.0411870939865474\ \(0\)\
\-\ other\\:\\ 0\\.04055902001148318\ \(0\)\
\-\ cells\\:\\ 0\\.0401170630639877\ \(0\)\
\-\ suited\\:\\ 0\\.03978295082314931\ \(0\)\
\-\ abundance\\:\\ 0\\.03978295082314931\ \(0\)\
\-\ interplay\\:\\ 0\\.03978295082314931\ \(0\)\
\-\ rationale\\:\\ 0\\.03978295082314931\ \(0\)\
\-\ kang\\:\\ 0\\.03978295082314931\ \(0\)\
\-\ bju\\:\\ 0\\.03978295082314931\ \(0\)\
\-\ at\\:\\ 0\\.03933290123339156\ \(0\)\
\-\ inhibit\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ ethnicity\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ batson\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ adherence\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ detects\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ ps\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ ba\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ fc\\:\\ 0\\.038470025488861165\ \(0\)\
\-\ well\\:\\ 0\\.03781681163888517\ \(0\)\
\-\ utilization\\:\\ 0\\.0374516414817988\ \(0\)\
\-\ molecules\\:\\ 0\\.0374516414817988\ \(0\)\
\-\ bind\\:\\ 0\\.0374516414817988\ \(0\)\
\-\ peptide\\:\\ 0\\.0374516414817988\ \(0\)\
\-\ 166\\:\\ 0\\.03661956116180681\ \(0\)\
\-\ gg\\:\\ 0\\.03661956116180681\ \(0\)\
\-\ wr\\:\\ 0\\.03661956116180681\ \(0\)\
\-\ storm\\:\\ 0\\.03661956116180681\ \(0\)\
\-\ es\\:\\ 0\\.03661956116180681\ \(0\)\
\-\ 50\\:\\ 0\\.036362442412977196\ \(0\)\
\-\ fibroblastic\\:\\ 0\\.03591604727539017\ \(0\)\
\-\ mj\\:\\ 0\\.03591604727539017\ \(0\)\
\-\ left\\:\\ 0\\.03552253311616306\ \(0\)\
\-\ 30\\:\\ 0\\.03551929448110427\ \(0\)\
\-\ which\\:\\ 0\\.03551322892617946\ \(0\)\
\-\ areas\\:\\ 0\\.035350035877263195\ \(0\)\
\-\ rev\\:\\ 0\\.03476909683475245\ \(0\)\
\-\ plays\\:\\ 0\\.034288251820456306\ \(0\)\
\-\ environment\\:\\ 0\\.034288251820456306\ \(0\)\
\-\ jun\\:\\ 0\\.034288251820456306\ \(0\)\
\-\ patient\\:\\ 0\\.03386970991694017\ \(0\)\
\-\ while\\:\\ 0\\.03365001030644526\ \(0\)\
\-\ themselves\\:\\ 0\\.03345617150046431\ \(0\)\
\-\ int\\:\\ 0\\.03345617150046431\ \(0\)\
\-\ reaches\\:\\ 0\\.033090872064757484\ \(0\)\
\-\ mar\\:\\ 0\\.033090872064757484\ \(0\)\
\-\ show\\:\\ 0\\.03305347349628859\ \(0\)\
\-\ traveling\\:\\ 0\\.032752657614047664\ \(0\)\
\-\ only\\:\\ 0\\.032528649503836375\ \(0\)\
\-\ prostatic\\:\\ 0\\.03214324616617617\ \(0\)\
\-\ seem\\:\\ 0\\.03214324616617617\ \(0\)\
\-\ epidemiology\\:\\ 0\\.03214324616617617\ \(0\)\
\-\ derived\\:\\ 0\\.03186656711841321\ \(0\)\
\-\ radiopharmaceutical\\:\\ 0\\.03160570717340995\ \(0\)\
\-\ why\\:\\ 0\\.03160570717340995\ \(0\)\
\-\ pleuritic\\:\\ 0\\.031358954833386375\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.0311248621591138\ \(0\)\
\-\ through\\:\\ 0\\.030994379470656978\ \(0\)\
\-\ selective\\:\\ 0\\.030902193286993306\ \(0\)\
\-\ however\\:\\ 0\\.030817710474965114\ \(0\)\
\-\ periarticular\\:\\ 0\\.030689884933685095\ \(0\)\
\-\ shows\\:\\ 0\\.03055895765694432\ \(0\)\
\-\ research\\:\\ 0\\.030487015687313164\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.030487015687313164\ \(0\)\
\-\ evolution\\:\\ 0\\.030487015687313164\ \(0\)\
\-\ predilection\\:\\ 0\\.030106478152051433\ \(0\)\
\-\ axial\\:\\ 0\\.030075902449307634\ \(0\)\
\-\ chance\\:\\ 0\\.029927482403414987\ \(0\)\
\-\ dec\\:\\ 0\\.029927482403414987\ \(0\)\
\-\ favorable\\:\\ 0\\.029755242846355594\ \(0\)\
\-\ mcp\\:\\ 0\\.029755242846355594\ \(0\)\
\-\ find\\:\\ 0\\.029755242846355594\ \(0\)\
\-\ fracture\\:\\ 0\\.02959160006334308\ \(0\)\
\-\ these\\:\\ 0\\.029402354587362796\ \(0\)\
\-\ resorption\\:\\ 0\\.029274397832059443\ \(0\)\
\-\ needs\\:\\ 0\\.029124751423007175\ \(0\)\
\-\ reason\\:\\ 0\\.028979856504833673\ \(0\)\
\-\ cl\\:\\ 0\\.028839420606630736\ \(0\)\
\-\ tc99m\\:\\ 0\\.028703177457070708\ \(0\)\
\-\ parathyroid\\:\\ 0\\.0285708839456428\ \(0\)\
\-\ begins\\:\\ 0\\.0285708839456428\ \(0\)\
\-\ 87\\:\\ 0\\.0285708839456428\ \(0\)\
\-\ united\\:\\ 0\\.028442317512067453\ \(0\)\
\-\ skeleton\\:\\ 0\\.028317273893469663\ \(0\)\
\-\ consistent\\:\\ 0\\.028232045480541222\ \(0\)\
\-\ cancers\\:\\ 0\\.027961472497771304\ \(0\)\
\-\ directed\\:\\ 0\\.02742393350500508\ \(0\)\
\-\ decade\\:\\ 0\\.02742393350500508\ \(0\)\
\-\ differentiate\\:\\ 0\\.02742393350500508\ \(0\)\
\-\ elderly\\:\\ 0\\.02742393350500508\ \(0\)\
\-\ imaging\\:\\ 0\\.027363089619822503\ \(0\)\
\-\ increases\\:\\ 0\\.027323626025970663\ \(0\)\
\-\ role\\:\\ 0\\.027323626025970663\ \(0\)\
\-\ can\\:\\ 0\\.02732323098376026\ \(0\)\
\-\ pathological\\:\\ 0\\.02712939217777931\ \(0\)\
\-\ black\\:\\ 0\\.026677160464588713\ \(0\)\
\-\ it\\:\\ 0\\.026652485527825395\ \(0\)\
\-\ staging\\:\\ 0\\.026591853185013094\ \(0\)\
\-\ hormone\\:\\ 0\\.026508111265280226\ \(0\)\
\-\ collagen\\:\\ 0\\.026425878291362667\ \(0\)\
\-\ treat\\:\\ 0\\.026345100844989523\ \(0\)\
\-\ may\\:\\ 0\\.026201870181151374\ \(0\)\
\-\ matrix\\:\\ 0\\.026187712607826607\ \(0\)\
\-\ evaluating\\:\\ 0\\.026187712607826607\ \(0\)\
\-\ produce\\:\\ 0\\.026111008170716942\ \(0\)\
\-\ drugs\\:\\ 0\\.026035571633761793\ \(0\)\
\-\ making\\:\\ 0\\.026035571633761793\ \(0\)\
\-\ 2006\\:\\ 0\\.025961361761664675\ \(0\)\
\-\ paget\\:\\ 0\\.025816466843491172\ \(0\)\
\-\ induced\\:\\ 0\\.025816466843491172\ \(0\)\
\-\ but\\:\\ 0\\.02574732488468844\ \(0\)\
\-\ presents\\:\\ 0\\.025047023567009767\ \(0\)\
\-\ treatment\\:\\ 0\\.024802382774838306\ \(0\)\
\-\ comparison\\:\\ 0\\.024798082836428804\ \(0\)\
\-\ each\\:\\ 0\\.02468539052869004\ \(0\)\
\-\ helpful\\:\\ 0\\.02468539052869004\ \(0\)\
\-\ re\\:\\ 0\\.024575413964308308\ \(0\)\
\-\ workup\\:\\ 0\\.02452140378866584\ \(0\)\
\-\ advanced\\:\\ 0\\.02446802532547186\ \(0\)\
\-\ images\\:\\ 0\\.02408455873147726\ \(0\)\
\-\ order\\:\\ 0\\.024062086203798325\ \(0\)\
\-\ develop\\:\\ 0\\.023966002516436814\ \(0\)\
\-\ thus\\:\\ 0\\.02391870876080982\ \(0\)\
\-\ different\\:\\ 0\\.023825566618233873\ \(0\)\
\-\ has\\:\\ 0\\.023782791970234213\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.023779698829366435\ \(0\)\
\-\ metabolic\\:\\ 0\\.023600703080729986\ \(0\)\
\-\ plexus\\:\\ 0\\.023470917844483005\ \(0\)\
\-\ replacement\\:\\ 0\\.023386400492486473\ \(0\)\
\-\ unusual\\:\\ 0\\.02334472160393773\ \(0\)\
\-\ rarely\\:\\ 0\\.02322192119333635\ \(0\)\
\-\ veins\\:\\ 0\\.02310233863387626\ \(0\)\
\-\ 33\\:\\ 0\\.022909744378509022\ \(0\)\
\-\ states\\:\\ 0\\.022872181972419296\ \(0\)\
\-\ current\\:\\ 0\\.022797972100322174\ \(0\)\
\-\ recently\\:\\ 0\\.02272494963725395\ \(0\)\
\-\ 29\\:\\ 0\\.022688871927028453\ \(0\)\
\-\ urinary\\:\\ 0\\.022512641283945735\ \(0\)\
\-\ incidence\\:\\ 0\\.022410079516608224\ \(0\)\
\-\ must\\:\\ 0\\.022309772037573804\ \(0\)\
\-\ reaction\\:\\ 0\\.02214734184823891\ \(0\)\
\-\ by\\:\\ 0\\.022110764151030762\ \(0\)\
\-\ surface\\:\\ 0\\.021721076951087916\ \(0\)\
\-\ until\\:\\ 0\\.021663306476191854\ \(0\)\
\-\ pathologic\\:\\ 0\\.02133124685659266\ \(0\)\
\-\ via\\:\\ 0\\.021278178740315044\ \(0\)\
\-\ site\\:\\ 0\\.020996846703285662\ \(0\)\
\-\ bones\\:\\ 0\\.02094750777326781\ \(0\)\
\-\ as\\:\\ 0\\.020917252785414335\ \(0\)\
\-\ references\\:\\ 0\\.02075531909946732\ \(0\)\
\-\ tissues\\:\\ 0\\.020525933807331347\ \(0\)\
\-\ where\\:\\ 0\\.020459307710519445\ \(0\)\
\-\ bladder\\:\\ 0\\.020202123808064368\ \(0\)\
\-\ symptomatic\\:\\ 0\\.02001832152230452\ \(0\)\
\-\ uptake\\:\\ 0\\.02001832152230452\ \(0\)\
\-\ use\\:\\ 0\\.019919319666673888\ \(0\)\
\-\ necrosis\\:\\ 0\\.019899774426621268\ \(0\)\
\-\ ct\\:\\ 0\\.01982248199148009\ \(0\)\
\-\ related\\:\\ 0\\.019784228848031948\ \(0\)\
\-\ are\\:\\ 0\\.0197571444672949\ \(0\)\
\-\ unknown\\:\\ 0\\.019727534869561875\ \(0\)\
\-\ pleural\\:\\ 0\\.019597925160961566\ \(0\)\
\-\ thoracic\\:\\ 0\\.019454171337075003\ \(0\)\
\-\ its\\:\\ 0\\.01926362422191944\ \(0\)\
\-\ throughout\\:\\ 0\\.019146382376231303\ \(0\)\
\-\ metastasis\\:\\ 0\\.0190807149616153\ \(0\)\
\-\ view\\:\\ 0\\.01906444468920698\ \(0\)\
\-\ diagnosed\\:\\ 0\\.018858046089494804\ \(0\)\
\-\ pain\\:\\ 0\\.0186315697971525\ \(0\)\
\-\ 25\\:\\ 0\\.01844286848981466\ \(0\)\
\-\ typically\\:\\ 0\\.018275881328981017\ \(0\)\
\-\ location\\:\\ 0\\.018127998369168934\ \(0\)\
\-\ this\\:\\ 0\\.017891236691970267\ \(0\)\
\-\ less\\:\\ 0\\.01771109564885709\ \(0\)\
\-\ back\\:\\ 0\\.01736254414598885\ \(0\)\
\-\ radiation\\:\\ 0\\.017252034955525304\ \(0\)\
\-\ white\\:\\ 0\\.01717624045891847\ \(0\)\
\-\ radiograph\\:\\ 0\\.01695612905762804\ \(0\)\
\-\ between\\:\\ 0\\.016915380513915213\ \(0\)\
\-\ radiographs\\:\\ 0\\.016885056106155805\ \(0\)\
\-\ known\\:\\ 0\\.016854931860962024\ \(0\)\
\-\ found\\:\\ 0\\.01684493447125375\ \(0\)\
\-\ will\\:\\ 0\\.01675593000533139\ \(0\)\
\-\ onset\\:\\ 0\\.01671692287405096\ \(0\)\
\-\ usually\\:\\ 0\\.01638912411422986\ \(0\)\
\-\ years\\:\\ 0\\.015958256575325434\ \(0\)\
\-\ lung\\:\\ 0\\.015836547853899652\ \(0\)\
\-\ his\\:\\ 0\\.015788758866697453\ \(0\)\
\-\ level\\:\\ 0\\.01572580881243373\ \(0\)\
\-\ when\\:\\ 0\\.01572580881243373\ \(0\)\
\-\ lymphoma\\:\\ 0\\.015504628704500898\ \(0\)\
\-\ 10\\:\\ 0\\.015223134821750032\ \(0\)\
\-\ therapy\\:\\ 0\\.01495799928367802\ \(0\)\
\-\ cell\\:\\ 0\\.014892426222044309\ \(0\)\
\-\ common\\:\\ 0\\.014764040637137602\ \(0\)\
\-\ patients\\:\\ 0\\.014645331241037295\ \(0\)\
\-\ over\\:\\ 0\\.014475833532409317\ \(0\)\
\-\ acute\\:\\ 0\\.014083189457816593\ \(0\)\
\-\ increased\\:\\ 0\\.014077740135883414\ \(0\)\
\-\ man\\:\\ 0\\.01378251810068758\ \(0\)\
\-\ associated\\:\\ 0\\.013721666444813306\ \(0\)\
\-\ present\\:\\ 0\\.013358692515692758\ \(0\)\
\-\ multiple\\:\\ 0\\.012733606845510349\ \(0\)\
\-\ after\\:\\ 0\\.012629332563464938\ \(0\)\
\-\ lesion\\:\\ 0\\.012481093335047632\ \(0\)\
\-\ male\\:\\ 0\\.011591166095532878\ \(0\)\
\-\ that\\:\\ 0\\.011297611857437552\ \(0\)\
\-\ normal\\:\\ 0\\.010629349734943042\ \(0\)\
\-\ there\\:\\ 0\\.010358693924924918\ \(0\)\
\-\ not\\:\\ 0\\.010277451243627198\ \(0\)\
\-\ an\\:\\ 0\\.009955166325937254\ \(0\)\
\-\ mass\\:\\ 0\\.00994414529528116\ \(0\)\
\-\ or\\:\\ 0\\.009056630491623141\ \(0\)\
